New partnership to accelerate drug discovery
A new partnership between the Universities of Nottingham and Strathclyde and pharmaceutical company GSK will accelerate research into the discovery of new medicines.
The five-year ESPRC funded programme will see the partners deliver a new suite of methods and approaches to tackle some of the major challenges in the discovery, development, and manufacture of medicines. The total project funding is £12.9 million, including a £5.5 million grant award from the EPSRC.
The research programme aims to enable the production of transformative medicines at lower costs with reduced waste production and shorter time for manufacture.
Researchers will apply cutting edge Artificial Intelligence and machine-learning technologies to the efficient identification of next generation medicines.
They will also aim to improve the production process of medicines, with a focus on sustainability through reducing environmental impact, developing more efficient preparation methods, and improving equipment efficiency using digital manufacturing technologies.
The integration of the research undertaken in these areas combined with the world leading scientific expertise at each of the partner institutions will make a major contribution across the pharmaceutical sector and lead to the faster development of transformative medicines to help people do more, feel better and live longer.
For more, read the press release - July 2019